NCT06531824ClinicalTrials.gov

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

RecruitingTaking participants now, according to the registry record.

Contact this study

In brief

Phase 311,000 participants sought557 sites20 countries

Registered in 1 registry

ClinicalTrials.govNCT06531824Open this record at ClinicalTrials.govSynced 2 days ago

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2024-08-01; recorded start 2024-08-30
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Present: Uses blinding (masking)A masking level is recorded in the record
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 1218 other studies in this databaseCounted from the lead sponsor named in the record (Boehringer Ingelheim)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding20/20
Quadruple-blind
Control arm13/15
Placebo / sham control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
Multi-centre8/8
Multi-centre: 480 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleMEGA

A very large study, international in scope: 11,000 participants (target), run at 557 sites, across 20 countries.

How this score is built

Enrolment38/40
11,000 participants (target)
Site count25/25
480 sites
Country count15/15
20 countries
Planned duration9/10
Planned over about 49 months
Sponsor scale10/10
Boehringer Ingelheim has led 1,211 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation. After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study. The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.

Conditions

Kidney Disease, Chronic

Eligibility

Eligibility
Sex	All
Ages	18 Years – No maximum
Healthy volunteers	No

Eligibility as written in the registry

Key Inclusion Criteria: * Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires: 1. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR ≥20 \<45 mL/min/1.73m² (irrespective of diabetes status); or 2. No self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with urine albumin-to-creatinine ratio (uACR) ≥150 mg/g (or protein-to-creatinine ratio ≥225 mg/g); or 3. Self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with uACR ≥30 mg/g (or protein-to-creatinine ratio ≥45 mg/g). * Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate. Key Exclusion Criteria: * Blood potassium of \>5.2 mmol/L at screening visit * Blood Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \>3x Upper Limit of Normal (ULN) at Screening visit (only one is required, with ALT preferred) * Known liver cirrhosis * On dialysis, functioning kidney transplant, or scheduled living donor transplant * Treated with new immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days * Receiving more than one Renin-Angiotensin System (RAS) inhibitor (i.e. on dual therapy with two of an Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB) or direct renin inhibitor) * Currently treated with an Mineralocorticoid Receptor Antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone) * Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study type	Interventional
Phase	Phase 3
Allocation	Randomised
Intervention model	PARALLEL
Primary purpose	TREATMENT
Masking	QUADRUPLE (4)
Enrolment	11,000 participants sought

Sponsor and collaborators

Boehringer Ingelheim Sponsor

Arms and interventions

Part 1: Run-in period (all participants)OTHER
* Participant will receive empagliflozin (called Type E) together with study tablets (called Type F) prior to later randomisation to the main study treatment (Type M). * This run-in period allows empagliflozin to be established and have its effects on kidney function before randomisation, and to make sure participant can tolerate empagliflozin long-term. Participants will not routinely know whether type F treatment is active or inactive so that participants can become familiar with taking main study tablet (Type M) after randomization.
Part 2: Randomized treatment, follow-up period, treatment groupEXPERIMENTAL
Part 2: Follow-up period, placebo groupPLACEBO_COMPARATOR

Interventions

Drug BI 690517
BI 690517 (called Type M randomized treatment)
Drug Empagliflozin
Empagliflozin (called Type E)
Drug Placebo matching BI 690517
Placebo matching BI 690517

Outcome measures

Primary outcome
Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.
Kidney disease progression is defined as kidney failure or a sustained decline of ≥40% in estimated Glomerular Filtration Rate (eGFR) from randomization
Time frame up to 4 years
Secondary outcome
Key secondary outcome: Time to first event of kidney failure, hospitalization for heart failure or cardiovascular death
Time frame up to 4 years
Secondary outcome
Key secondary outcome: Time to first event of hospitalization for heart failure or cardiovascular death
Time frame up to 4 years
Secondary outcome
Key secondary outcome: Occurrences of hospitalizations from any cause (first and any subsequent, combined) or death from any cause
Time frame up to 4 years
Secondary outcome
Key secondary outcome: Time to death from any cause
Time frame up to 4 years
Secondary outcome
Key secondary outcome: Annual rate of change in eGFR from 1 month until last scheduled visit (i.e. chronic eGFR slope)
Time frame up to 4 years
Secondary outcome
Time to first event of kidney disease progression or cardiovascular death
Time frame up to 4 years

Dates

Dates
Start date	August 30, 2024 (actual)
Primary completion	August 30, 2028 (estimated)
Completion	August 30, 2028 (estimated)
First posted	August 1, 2024 (actual)
Last updated	September 17, 2026
Results posted	Not stated in the registry record
Status last verified	September 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

557 sites are recruiting

Argentina

Argentina
Facility	City	Status
Fundacion INTECNUS	Bariloche	Recruiting
Terapia Renal Domiciliaria	Buenos Aires	Recruiting
Centro de Salud Renal Junin SRL	Buenos Aires	Recruiting
Dres. Iribarren & Asoc. Consultario	Buenos Aires	Recruiting
Glenny Corp - Centro Medico Saavedra	Buenos Aires	Recruiting
CPSIC SRL - Cardiologia Palermo	CABA	Recruiting
Sanatorio Pasteur S.A	Catamarca	Recruiting
CEMIC	Ciudad Autonoma Buenos Aires	Recruiting
CIMEL Chahin - Chahin S.A.	Lanús Este	Recruiting
Centro Nefrologico del Mar	Mar del Plata	Recruiting
Mains Bleues	Rafaela	Recruiting
Sanatorio Parque S.A.	Rosario	Recruiting
Hospital Privado de Rosario	Rosario	Recruiting
Instituto de Nefrourologia y Nutricion de Salta	Salta	Recruiting
Clinica El Castaño	San Juan	Recruiting
Centro de Investigaciones Medicas Tucuman	San Miguel de Tucumán	Recruiting
Centro Integral de Medicina Respiratoria - CIMER	San Miguel de Tucumán	Recruiting
Instituto de Investigaciones Clinicas de Rosario	Santa Fe	Recruiting
CEREHA S.A.- Centro de Estudios Renales e Hipertension Arterial	Villa Domínico	Recruiting

Australia

Australia
Facility	City	State or region	Status
Flinders Medical Centre	Bedford Park	South Australia	Recruiting
Eastern Health-Box Hill Hospital	Box Hill	Victoria	Recruiting
Renal Research, Gosford	Gosford	New South Wales	Recruiting
Austin Health	Heidelberg Heights	Victoria	Recruiting
St George Hospital	Kogarah	New South Wales	Recruiting
Liverpool Hospital	Liverpool	New South Wales	Recruiting
The Alfred Hospital	Melbourne	Victoria	Recruiting
St Vincent's Hospital Melbourne	Melbourne	Victoria	Recruiting
Macquarie University	New South Wales		Recruiting
Westmead Hospital	New South Wales		Recruiting
Hervey Bay Hospital	Pialba	Queensland	Recruiting
Port Macquarie Base Hospital (PMBH)	Port Macquarie	New South Wales	Recruiting
Griffith University	Southport	Queensland	Recruiting
Sunshine Hospital	St Albans	Victoria	Recruiting
Toowoomba Hospital	Toowoomba	Queensland	Recruiting

Belgium

Belgium
Facility	City	Status
AZ Sint-Jan Brugge	Bruges	Recruiting
Ziekenhuis Oost-Limburg	Genk	Recruiting
UZ Brussel	Jette	Recruiting
Centre Hospitalier Universitaire de Liège	Liège	Recruiting

Brazil

Brazil
Facility	City	Status
Centro de Pesquisa Clínica do Coração	Aracaju	Recruiting
Santa Casa de Belo Horizonte	Belo Horizonte	Recruiting
Centro de Pesquisa do Hospital Evangelico de Belo Horizonte	Belo Horizonte	Recruiting
Universidade Estadual Paulista "Julio De Mesquita Filho"	Botucatu	Recruiting
Hospital Universitário São Francisco na Providência de Deus	Bragança Paulista	Recruiting
CEG - Centro de Endocrinologia Geloneze	Campinas	Recruiting
Instituto Cardiovascular de Linhares Ltda	Centro Linhares	Recruiting
PUC Trials - Núcleo de Pesquisa Clínica da Escola de Medicina da PUC-PR	Curitiba	Recruiting
Hospital Universitário Walter Cantídio - UFC	Fortaleza	Recruiting
Centro de Pesquisas em Diabetes e Doencas Metabolicas	Fortaleza	Recruiting
Hospital Ruy Azeredo	Goiânia	Recruiting
Clínica CENDI Endocrinologia e Diabetes	Goiânia	Recruiting

507 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

September 17, 2026
Site added
37 sites added (557 total)
520557
September 2, 2026
Site added
5 sites added (520 total)
515520
August 21, 2026
Site added
18 sites added (515 total)
497515
August 10, 2026
Site added
17 sites added (497 total)
480497

Registry: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06531824

Categories

Registered in 1 registry

Interested in this study?

How this study is set up

Summary

Conditions

Eligibility

Eligibility as written in the registry

Eligibility in plain statements

Study design

Sponsor and collaborators

Arms and interventions

Interventions

Outcome measures

Dates

Locations

Argentina

Australia

Belgium

Brazil

Study documents

Changes over time